Valuation: Filana Therapeutics, Inc.

Market Cap 57.97M 50.83M 46.85M 43.86M 82.25M 5.47B 83.96M 563M 218M 2.7B 218M 213M 9.37B P/E 2026 *
-1.26x
P/E 2027 * -1.01x
Enterprise Value 57.97M 50.83M 46.85M 43.86M 82.25M 5.47B 83.96M 563M 218M 2.7B 218M 213M 9.37B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
88.98%
Yield 2026 *
-
Yield 2027 * -
1 day+3.45%
1 week-1.64%
Current month-22.08%
1 month-22.58%
3 months-28.14%
6 months-44.95%
Current year-39.39%
1 week 1.15
Extreme 1.15
1.27
1 month 1.15
Extreme 1.15
1.6
Current year 1.15
Extreme 1.15
2.49
1 year 1.15
Extreme 1.15
4.98
3 years 1.15
Extreme 1.15
42.2
5 years 1.15
Extreme 1.15
146.16
10 years 0.76
Extreme 0.76
146.16
Manager TitleAgeSince
Chief Executive Officer 67 2024-09-05
Director of Finance/CFO 57 2018-09-30
Chief Tech/Sci/R&D Officer 70 2025-08-06
Director TitleAgeSince
Director/Board Member 88 2003-02-28
Director/Board Member 78 2007-12-06
Chairman 67 2024-07-16
Date Insider Type Main position Quantity % Market Cap.
11-23Buy

Director

8,600 0.0178%
11-19Buy

Chief Executive Officer

150,000 0.3105%
11-18Buy

Chief Executive Officer

73,385 0.1519%
Change 5-day change 1-year change 3-year change Capi.($)
+3.45%-1.64%-31.43%-94.95% 57.97M
+0.28%-1.16%+67.48%+122.32% 55.63B
+0.82%+15.05%+79.52%+88.67% 52.25B
+1.36%+0.36%-14.52%-14.67% 23.07B
-1.04%+7.91%+3.91%+413.05% 22.41B
+6.78%+14.77%+37.54%-1.86% 17.32B
+0.40%+3.23%+29.96%-32.58% 15.94B
+2.89%+5.51%+25.42%+188.41% 13.77B
-3.35%+8.96%+134.32%+282.61% 13.47B
+4.21%+11.01%+33.13% - 12.43B
Average +1.58%+4.13%+36.53%+105.67% 22.63B
Weighted average by Cap. +1.06%+5.13%+50.18%+122.47%

Financials

2026 *2027 *
Net sales - -
Net income -48.43M -42.46M -39.14M -36.64M -68.71M -4.57B -70.14M -470M -182M -2.26B -182M -178M -7.83B -60M -52.61M -48.49M -45.4M -85.13M -5.66B -86.9M -583M -226M -2.8B -225M -220M -9.7B
Net Debt - -
Logo Filana Therapeutics, Inc.
Filana Therapeutics, Inc., formerly Cassava Sciences, Inc., is a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, is an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
Employees
19
Date Price Change Volume
26-06-29 US$1.219 +1.58% 16,004
26-06-26 US$1.200 +3.45% 358,560
26-06-25 US$1.160 -1.69% 340,733
26-06-24 US$1.180 -0.84% 210,215
26-06-23 US$1.190 -4.03% 346,871
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.200USD
Average target price
6.500USD
Spread / Average Target
+441.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FLNA Stock